ARGENX SE (ARGX.BR) Stock Price, Forecast & Analysis
Europe - Euronext Brussels - EBR:ARGX - NL0010832176 - Common Stock
ARGX.BR Key Statistics, Chart & Performance
The current stock price of ARGX.BR is 782.4 EUR. In the past month the price increased by 10.88%. In the past year, price increased by 33.42%.
ARGX.BR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 72.89 | 48.25B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.41B | ||
| ABVX.PA | ABIVAX SA | N/A | 8.41B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.39B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.78B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.78B | ||
| 5CV.DE | CUREVAC NV | 5.45 | 1.07B | ||
| NANO.PA | NANOBIOTIX | N/A | 837.02M | ||
| PHIL.MI | PHILOGEN SPA | 21.14 | 704.68M | ||
| IVA.PA | INVENTIVA SA | N/A | 699.13M | ||
| 6IV.DE | INVENTIVA SA | N/A | 651.37M | ||
| ALCLS.PA | CELLECTIS | N/A | 444.94M |
Related stock screener links
About ARGX.BR
Company Profile
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. The company is headquartered in Amsterdam, Noord-Holland and currently employs 1,599 full-time employees. The company went IPO on 2014-07-10. The company is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
Company Info
ARGENX SE
Laarderhoogtweg 25
Amsterdam NOORD-HOLLAND NL
Employees: 1599
Phone: 31763030
ARGENX SE / ARGX.BR FAQ
What does ARGX do?
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. The company is headquartered in Amsterdam, Noord-Holland and currently employs 1,599 full-time employees. The company went IPO on 2014-07-10. The company is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
What is the stock price of ARGENX SE today?
The current stock price of ARGX.BR is 782.4 EUR. The price decreased by -1.06% in the last trading session.
What is the dividend status of ARGENX SE?
ARGX.BR does not pay a dividend.
How is the ChartMill rating for ARGENX SE?
ARGX.BR has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Is ARGENX SE (ARGX.BR) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ARGX.BR.
How many employees does ARGENX SE have?
ARGENX SE (ARGX.BR) currently has 1599 employees.
Can you provide the market cap for ARGENX SE?
ARGENX SE (ARGX.BR) has a market capitalization of 48.17B EUR. This makes ARGX.BR a Large Cap stock.
ARGX.BR Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ARGX.BR. When comparing the yearly performance of all stocks, ARGX.BR is one of the better performing stocks in the market, outperforming 91.81% of all stocks.
ARGX.BR Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to ARGX.BR. While ARGX.BR has a great health rating, its profitability is only average at the moment.
ARGX.BR Financial Highlights
Over the last trailing twelve months ARGX.BR reported a non-GAAP Earnings per Share(EPS) of 10.75. The EPS increased by 1512.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 41.97% | ||
| ROA | 17.84% | ||
| ROE | 21% | ||
| Debt/Equity | 0.01 |
ARGX.BR Forecast & Estimates
25 analysts have analysed ARGX.BR and the average price target is 827.21 EUR. This implies a price increase of 5.73% is expected in the next year compared to the current price of 782.4.
For the next year, analysts expect an EPS growth of 867.29% and a revenue growth 89.57% for ARGX.BR